Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation

Atrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardiover...

Full description

Bibliographic Details
Main Authors: N. A. Novikova, A. N. Volovchenko
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-11-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/1341
id doaj-a69a3f4de8274935acf0154e5529ba66
record_format Article
spelling doaj-a69a3f4de8274935acf0154e5529ba662021-09-03T13:15:25ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-11-0112559059410.20996/1819-6446-2016-12-5-590-5941267Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial FibrillationN. A. Novikova0A. N. Volovchenko1I.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991 RussiaI.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991 RussiaAtrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However lately new oral anticoagulants (NOAC) are becoming more common for the prevention of thromboembolic events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has been shown in a retrospective analysis of patients from the RE-LY study. The incidence of stroke and systemic embolism within 30 days after cardioversion was low and did not differ significantly in all groups. Thus, the results of the RE-LY study allow performing the planned and emergency cardioversion in patients receiving dabigatran. These results were later confirmed in other retrospective studies and meta-analyzes that are presented in this article. The X-VERT study and sub-analysis of the ARISTOTLE study showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical cardioversion in patients with non-valvular AF. Long-term preparation courses for the cardioversion were used in the majority of patients in all published papers. By the present time a specially designed study directly aimed at assessing the NOAC effectiveness, in particular, dabigatran, in preparing and performing electrical cardioversion was not carried out in patients with AF. Some questions about the safety and efficacy of dabigatran during short preparation courses before electrical cardioversion remain.https://www.rpcardio.com/jour/article/view/1341atrial fibrillationelectrical cardioversionwarfarindabigatran
collection DOAJ
language English
format Article
sources DOAJ
author N. A. Novikova
A. N. Volovchenko
spellingShingle N. A. Novikova
A. N. Volovchenko
Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
Racionalʹnaâ Farmakoterapiâ v Kardiologii
atrial fibrillation
electrical cardioversion
warfarin
dabigatran
author_facet N. A. Novikova
A. N. Volovchenko
author_sort N. A. Novikova
title Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
title_short Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
title_full Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
title_fullStr Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
title_full_unstemmed Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
title_sort dabigatran etexilate in the course of electrical cardioversion in patients with non-valvular atrial fibrillation
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2016-11-01
description Atrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic stroke. The risk of thromboembolic complications increases significantly when performing for electrical cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However lately new oral anticoagulants (NOAC) are becoming more common for the prevention of thromboembolic events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has been shown in a retrospective analysis of patients from the RE-LY study. The incidence of stroke and systemic embolism within 30 days after cardioversion was low and did not differ significantly in all groups. Thus, the results of the RE-LY study allow performing the planned and emergency cardioversion in patients receiving dabigatran. These results were later confirmed in other retrospective studies and meta-analyzes that are presented in this article. The X-VERT study and sub-analysis of the ARISTOTLE study showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical cardioversion in patients with non-valvular AF. Long-term preparation courses for the cardioversion were used in the majority of patients in all published papers. By the present time a specially designed study directly aimed at assessing the NOAC effectiveness, in particular, dabigatran, in preparing and performing electrical cardioversion was not carried out in patients with AF. Some questions about the safety and efficacy of dabigatran during short preparation courses before electrical cardioversion remain.
topic atrial fibrillation
electrical cardioversion
warfarin
dabigatran
url https://www.rpcardio.com/jour/article/view/1341
work_keys_str_mv AT nanovikova dabigatranetexilateinthecourseofelectricalcardioversioninpatientswithnonvalvularatrialfibrillation
AT anvolovchenko dabigatranetexilateinthecourseofelectricalcardioversioninpatientswithnonvalvularatrialfibrillation
_version_ 1717816675744612352